NCT06100042

Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting

Multicentre, Prospective, Non-interventional Study Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Chiesi Italia · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G (beclomethasone/formoterol/glycopyrronium).

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	BDP/FF/G	BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths: * Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide); * High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide).

Timeline

• Start date: 2024-04-24
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2023-10-25
• Last updated: 2025-07-01

Locations

1 site across 1 country: Italy